8-K: Entrada Therapeutics Receives UK Authorization for Phase 1/2 Study of ENTR-601-45 in Duchenne Muscular Dystrophy

Entrada Therapeutics has been authorized in the UK to begin a Phase 1/2 clinical study of ENTR-601-45 for Duchenne Muscular Dystrophy (DMD) amenable to exon 45 skipping.

Summary

• Entrada Therapeutics announced it has received authorization from the UK's Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to initiate a Phase 1/2 clinical study of ENTR-601-45.
• The study, named ELEVATE-45-201, will evaluate the safety, tolerability, and effectiveness of ENTR-601-45 in ambulatory patients with DMD who are exon 45 skipping amenable.
• The company is on track to initiate the trial in the UK in the third quarter of 2025.
• The Phase 1/2 study is a global, two-part, randomized, double-blind, placebo-controlled trial.
• Part A will evaluate safety, pharmacokinetics, and pharmacodynamics in approximately 24 patients, with doses ranging from 5 mg/kg to 15 mg/kg administered every six weeks across three cohorts.
• Part B will further evaluate the optimal dose established in Part A for safety and efficacy, including functional outcomes and patient-reported quality of life measures.
• Study participants may be eligible for an open-label extension study to evaluate the long-term safety, efficacy, and tolerability of ENTR-601-45.
• ELEVATE-45 regulatory filings have been submitted in the EU, with regulatory review ongoing.
• ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025.

Sentiment

Score: 7

Explanation: The announcement is positive as it indicates progress in the clinical development of ENTR-601-45. The company is on track with its plans, and regulatory authorization has been received. However, the forward-looking statements and inherent risks associated with drug development temper the overall sentiment.

Positives

• The authorization from the UK regulatory agencies allows Entrada to proceed with clinical trials for ENTR-601-45, a potential treatment for DMD.
• The company is on track to initiate the ELEVATE-45-201 study in Q3 2025.
• The study design includes a comprehensive evaluation of safety, tolerability, and effectiveness, with a potential open-label extension for long-term assessment.
• The company expects to progress three Duchenne programs into global clinical development in 2025.

Risks

• The forward-looking statements are subject to risks and uncertainties, including those related to the identification and development of product candidates, the timing and availability of clinical trial results, and regulatory clearance.
• There is a risk that the company's cash resources may not be sufficient to fund operating expenses and capital expenditure requirements.
• Clinical trial results may not be predictive of later trial results.

Future Outlook

Entrada Therapeutics plans to initiate the ELEVATE-45-201 study in the UK in Q3 2025 and aims to progress three Duchenne programs into global clinical development in 2025.

Management Comments

• 'We are pleased to receive U.K. clearance for the second clinical program in our growing Duchenne franchise,' said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.
• 'Building on the momentum of our ELEVATE-44 program, this authorization brings us closer to having three Duchenne programs in clinical development by the end of this year.'
• 'To meet this urgency in Duchenne, we will continue our strategy of initiating and running studies in the U.K. and EU before sharing these study results with the FDA to potentially enable registrational studies in the U.S.'

Industry Context

This announcement reflects the ongoing efforts in the biopharmaceutical industry to develop targeted therapies for rare genetic diseases like Duchenne Muscular Dystrophy, with a focus on exon skipping technologies.

Comparison to Industry Standards

• Other companies developing exon-skipping therapies for DMD include Sarepta Therapeutics and NS Pharma.
• Sarepta's Exondys 51, Amondys 45, and Vyondys 53 are approved exon-skipping drugs for DMD, targeting specific exons.
• Entrada's approach using EEV-conjugated PMOs aims to improve intracellular delivery and efficacy compared to traditional PMO-based therapies.

Stakeholder Impact

• Positive impact on patients with Duchenne Muscular Dystrophy and their families, as ENTR-601-45 represents a potential new treatment option.
• Potential positive impact on shareholders if the clinical trials are successful and the drug is approved.
• Positive impact on employees of Entrada Therapeutics, as the company advances its clinical programs.

Next Steps

• Initiate the ELEVATE-45-201 Phase 1/2 clinical study in the UK in Q3 2025.
• Continue regulatory review for ELEVATE-45 in the EU.
• Advance the development of other Duchenne programs.

Key Dates

Keywords

Duchenne Muscular Dystrophy, ENTR-601-45, ELEVATE-45-201, Exon 45 Skipping, Clinical Trial, Entrada Therapeutics, Regulatory Authorization, EEV-therapeutics